AstraZeneca

News

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.

News

One in four diabetics has undiagnosed heart failure; study

A study has found that undiagnosed heart failure can be detected in people with high-risk diabetes using a simple, GP-led care pathway.

News

Where others missed, AZ's IL-33 drug hits the mark in COPD

AZ's IL-33 inhibitor tozorakimab hits the mark in two late-stage COPD trials, raising the prospects of a class that has had some failures in the past.

News

AstraZeneca reportedly hit by serious cyberattack

A hacking group claims to have broken into AstraZeneca's IT systems and stolen confidential data, which they are now offering for sale.

News

US court says pharma giants must face False Claims suit

An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.

AZ claims another win for Imfinzi in frontline liver cancer

AZ considers filings for long-acting Strensiq follow-up

One in four diabetics has undiagnosed heart failure; study

Where others missed, AZ's IL-33 drug hits the mark in COPD

AstraZeneca reportedly hit by serious cyberattack

US court says pharma giants must face False Claims suit

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

AstraZeneca

Editor's Picks